Grifols S.A. (GRF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Grifols S.A. (GRF) has a cash flow conversion efficiency ratio of 0.020x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€155.27 Million ≈ $181.52 Million USD) by net assets (€7.60 Billion ≈ $8.88 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Grifols S.A. market capitalisation for the company's overall valuation and market capitalisation.
Grifols S.A. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Grifols S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Grifols S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grifols S.A. ranked by their cash flow conversion efficiency. Explore how high is Grifols S.A.'s earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Icahn Enterprises LP
NASDAQ:IEP
|
0.239x |
|
Hangcha Group Co Ltd
SHG:603298
|
0.026x |
|
Boc International China Co Ltd
SHG:601696
|
0.345x |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
-0.001x |
|
AUTO TRADER ADR 1/4 LS-01
F:2UA0
|
N/A |
|
Spire Inc
NYSE:SR
|
13076.512x |
|
Shandong Himile Mechanical Science & Technology Co Ltd
SHE:002595
|
0.049x |
|
BRF S.A
F:P5Y
|
0.142x |
Annual Cash Flow Conversion Efficiency for Grifols S.A. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Grifols S.A. from 2005 to 2024. View today's stock price for Grifols S.A. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
€902.17 Million ≈ $1.05 Billion |
0.105x | +301.21% |
| 2023-12-31 | €7.97 Billion ≈ $9.32 Billion |
€208.28 Million ≈ $243.50 Million |
0.026x | +2133.27% |
| 2022-12-31 | €8.46 Billion ≈ $9.89 Billion |
€-10.87 Million ≈ $-12.70 Million |
-0.001x | -101.75% |
| 2021-12-31 | €8.15 Billion ≈ $9.52 Billion |
€596.98 Million ≈ $697.93 Million |
0.073x | -55.65% |
| 2020-12-31 | €6.72 Billion ≈ $7.86 Billion |
€1.11 Billion ≈ $1.30 Billion |
0.165x | +98.81% |
| 2019-12-31 | €6.85 Billion ≈ $8.00 Billion |
€568.93 Million ≈ $665.14 Million |
0.083x | -47.07% |
| 2018-12-31 | €4.70 Billion ≈ $5.49 Billion |
€737.43 Million ≈ $862.13 Million |
0.157x | -32.21% |
| 2017-12-31 | €3.63 Billion ≈ $4.25 Billion |
€841.75 Million ≈ $984.09 Million |
0.232x | +56.07% |
| 2016-12-31 | €3.73 Billion ≈ $4.36 Billion |
€553.28 Million ≈ $646.84 Million |
0.148x | -34.04% |
| 2015-12-31 | €3.30 Billion ≈ $3.86 Billion |
€742.78 Million ≈ $868.39 Million |
0.225x | -38.80% |
| 2014-12-31 | €2.66 Billion ≈ $3.11 Billion |
€978.93 Million ≈ $1.14 Billion |
0.368x | +30.85% |
| 2013-12-31 | €2.11 Billion ≈ $2.46 Billion |
€592.01 Million ≈ $692.12 Million |
0.281x | +4.19% |
| 2012-12-31 | €1.88 Billion ≈ $2.20 Billion |
€507.12 Million ≈ $592.87 Million |
0.270x | +103.85% |
| 2011-12-31 | €1.66 Billion ≈ $1.95 Billion |
€220.23 Million ≈ $257.47 Million |
0.132x | -10.25% |
| 2010-12-31 | €707.39 Million ≈ $827.01 Million |
€104.25 Million ≈ $121.88 Million |
0.147x | -3.31% |
| 2009-12-31 | €578.53 Million ≈ $676.36 Million |
€88.18 Million ≈ $103.09 Million |
0.152x | -0.07% |
| 2008-12-31 | €481.28 Million ≈ $562.67 Million |
€73.41 Million ≈ $85.82 Million |
0.153x | -33.90% |
| 2007-12-31 | €384.17 Million ≈ $449.13 Million |
€88.64 Million ≈ $103.63 Million |
0.231x | +73.19% |
| 2006-12-31 | €368.35 Million ≈ $430.64 Million |
€49.08 Million ≈ $57.38 Million |
0.133x | -93.77% |
| 2005-12-31 | €55.95 Million ≈ $65.41 Million |
€119.72 Million ≈ $139.97 Million |
2.140x | -- |
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more